about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Pli­ant Ther­a­peu­tics re­leas­es longer-term safe­ty, pre­lim­i­nary ef­fi­ca­cy da­ta from PhI­Ia study

3 years ago
R&D

M&A vibes amid earn­ings sea­son; CAR-T be­yond can­cer; Lil­ly dou­bles down on obe­si­ty; Two con­se­quen­tial FDA ap­provals; ...

3 years ago
Weekly

Am­gen bows out of PhI­Ib tri­als test­ing bis­pe­cif­ic, fu­sion pro­tein for lu­pus

3 years ago
R&D

Sanofi scraps top­i­cal BTK drug from $3.7B Prin­cip­ia buy­out

3 years ago
R&D

Eli Lil­ly show­cas­es PhI­II weight loss da­ta for type 2 di­a­betes pa­tients tak­ing tirzepatide

3 years ago
R&D

As­traZeneca cuts Alex­ion's PhI­II Wil­son dis­ease drug, takes $244M write­down

3 years ago
R&D

GSK ends PhI­II Ze­ju­la tri­al af­ter run­ning in­to chal­lenges en­rolling pa­tients

3 years ago
R&D

Roche's Q1 pipeline cleanup claims PhII myelofi­bro­sis drug, ear­ly-stage MAGE-A4 work

3 years ago
R&D

CAR-T re­shaped can­cer treat­ment. Can it change au­toim­mune dis­ease, too?

3 years ago
Cell/Gene Tx
In Focus

No­var­tis pays Ger­man biotech $40M for ra­di­oli­gand ther­a­py, di­ag­nos­tic hit­ting 'first-in-class' tar­get

3 years ago
Deals

Up­dat­ed: No­var­tis trims pipeline by 10% as Vas Narasimhan places pre­mi­um on 'high-val­ue med­i­ci­nes'

3 years ago
R&D

Uni­ty touts PhII win, plots head-to-head with Re­gen­eron drug in 'defin­ing mo­men­t'

3 years ago
R&D

Mer­ck’s $10.8B Prometheus buy­out, GSK’s $2B Bel­lus takeover fu­el M&A buzz; CAR-T da­ta leak; Best of #AACR23; and ...

3 years ago
Weekly

Chi­nese biotech start­up adds $315M to the bank af­ter bring­ing 5 Take­da drugs to its fold

3 years ago
Financing
China

Jun­shi Bio­sciences touts lung can­cer da­ta as it looks to ex­pand PD-1 la­bel in Chi­na again

3 years ago
R&D

Biden's long-await­ed NIH pick might be NCI chief Mon­i­ca Bertag­nol­li — re­ports

3 years ago
People

Gilde Health­care bags $657M to fu­el 'holis­tic' search for af­ford­able drugs, tech­nolo­gies

3 years ago
Financing

GSK will buy Bel­lus Health for $2B, set­ting up show­down with Mer­ck

3 years ago
Deals

Japan­ese CRO buys back pen­ny stock spin­out while await­ing FDA de­ci­sion on mi­graine can­di­date

3 years ago
Deals

Lat­est on re­ver­ber­a­tions of abor­tion pill rul­ing; Biotech ven­ture fund­ing dips; No­vo Nordisk dives in­to di­a­betes cell ...

3 years ago
Weekly

Sin­ga­pore­an cell ther­a­py biotech with off-the-shelf am­bi­tions wraps mod­est IPO

3 years ago
Financing

Biotech laser-fo­cused on a sin­gle tar­get nabs $105M for fi­bro­sis, can­cer tri­als

3 years ago
Financing

Mer­ck KGaA's BTK in­hibitor hit by par­tial clin­i­cal hold over safe­ty con­cern, but PhI­II read­out un­af­fect­ed

3 years ago
R&D
FDA+

Ex­tend­ed FTC re­view adds wrin­kle to Sanofi's $2.9B Proven­tion Bio buy­out

3 years ago
Deals
First page Previous page 12131415161718 Next page Last page
A service from the Financial Times